Allied Past Earnings Performance
Past criteria checks 0/6
Allied's earnings have been declining at an average annual rate of -22.8%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been growing at an average rate of 55.3% per year.
Key information
-22.8%
Earnings growth rate
-13.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 55.3% |
| Return on equity | n/a |
| Net Margin | -41,861.4% |
| Last Earnings Update | 29 Feb 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Allied makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Feb 24 | 0 | -9 | 4 | 0 |
| 30 Nov 23 | 0 | -10 | 5 | 0 |
| 31 Aug 23 | 0 | -11 | 5 | 0 |
| 31 May 23 | 0 | -6 | 6 | 0 |
| 28 Feb 23 | 0 | -7 | 6 | 0 |
| 30 Nov 22 | 0 | -7 | 6 | 0 |
| 31 Aug 22 | 0 | -16 | 14 | 0 |
| 31 May 22 | 0 | -20 | 14 | 0 |
| 28 Feb 22 | 0 | -20 | 14 | 0 |
| 30 Nov 21 | 0 | -20 | 15 | 0 |
| 31 Aug 21 | 0 | -11 | 6 | 0 |
| 31 May 21 | 0 | -11 | 6 | 0 |
| 28 Feb 21 | 0 | -9 | 5 | 0 |
| 30 Nov 20 | 0 | -7 | 3 | 0 |
| 31 Aug 20 | 0 | -7 | 3 | 0 |
| 31 May 20 | 0 | -3 | 2 | 0 |
| 29 Feb 20 | 0 | -3 | 2 | 0 |
| 30 Nov 19 | 0 | -2 | 1 | 0 |
| 31 Aug 19 | 0 | -1 | 1 | 0 |
Quality Earnings: ALID is currently unprofitable.
Growing Profit Margin: ALID is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALID is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.
Accelerating Growth: Unable to compare ALID's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALID is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: ALID's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.